AcquiSci has been able to leapfrog over classical animal modeling and Phase I clinical trials to Phase IIa clinical trial status for stroke; an immense cost and time savings, based on the strong documented safety profile generated from the use of oxidative stressed blood to treat clinical disease. As indicated estimated time to commercialization is between four (4) to five (5) years with average annual revenue of $468 million.

Development to Commercialization Time for Ischemic Stroke

Milestone: USPTO grants core technology and 1st Use application patents
Projected Timeline: Core grant awarded/1st Use patent applications (filed in the US and through the PCT) - June 2010

Milestone: Launch IIa trial in India; 2nd Quarter 2011
Milestone: Completion of Pilot Phase IIa stroke trial in India; 1st Quarter 2012
Projected Timeline: 9 months

Milestone: Launch Tier 1 EU County IIa trial; 2nd Quarter 2012
Milestone: Completion of Phase IIa stroke trial–Tier 1 EU country; 2nd Quarter 2013
Projected Timeline: 12 months

Milestone: Launch Pivotal Phase III stroke trial–Tier 1 EU country; 3rd Quarter 2013
Milestone: Completion of Pivotal Phase III stroke trial–Tier 1 EU country; 4th Quarter 2014/1st Quarter 2015
Projected Timeline: 12-15 months